AndreaBozzo/ceres-open-data-index huggingface dataset:
Auto-protective redox buffering systems in stimulated macrophages

Background
          Macrophages, upon encounter with micro-organisms or stimulated by cytokines, produce various effector molecules aimed at destroying the foreign agents and protecting the organism. Reactive oxygen species (ROS) and reactive nitrogen species (RNS) are front line molecules exerting strong cytotoxic activities against micro-organisms and many cells, including macrophages themselves. Using cells of the murine macrophage cell line (RAW 264.7) stimulated in vitro with lipopolysaccharide (LPS) and/or interferon (IFN-γ), which induce strong endogenous NO production, we examined by which mechanisms a fraction of activated macrophages protect themselves from nitrosative stress and manage to escape destruction?
        
        
          Results
          We observed that survivors (10–50% depending on the experiments) had acquired a resistant phenotype being capable to survive when further exposed in vitro to an apoptosis inducing dose of the NO donor compound DETA-NO. These cells expressed an increased steady-state levels of Mn SOD, CuZn SOD and catalase mRNA (130–200%), together with an increased activity of the corresponding enzymes. Intracellular concentration of glutathione was also increased (× 3.5 fold at 6 hours, still maintained × 5.2 fold at 48 hours). Neither mRNA for glutathione peroxydase, γ-glutamylcysteine synthase and glutathione reductase, nor thioredoxine and thioredoxine reductase, were significantly modified. Additional experiments in which RAW 264.7 cells were stimulated with LPS and/or IFN-γ in the presence of relatively specific inhibitors of both Mn and Cu/Zn SOD, aminotriazol (ATZ) catalase inhibitor and buthionine sulfoximine (BSO) glutathione inhibitor, showed that inhibiting LPS-induced up-regulation of intracellular redox buffering systems also prevented acquisition of the resistant phenotype.
        
        
          Conclusions
          Our data suggest a direct causal relationship between survival of a fraction of macrophages and a up-regulation of key sets of auto-protective intracellular redox buffering systems, occurring simultaneously with modulation of expression of apoptotic molecules of the Bcl2-Bcl-XL/Bax-Bad family.
Tobacco Product and Alcohol Use Tables  (Prevalence Estimates) - 2.1 to 2.84

These detailed tables are population tobacco and alcohol use totals and prevalence estimates from the 2011 National Survey on Drug Use and Health (NSDUH). Tobacco products include cigarettes, smokeless tobacco, cigars, and pipe tobacco. Alcohol use includes binge and heavy alcohol use. Results are provided for lifetime, past year, and past month use by age group, gender, race/ethnicity, education level, employment status, and geographic area. Comparisons are made between 2011 and 2010.
Compound 529472: N-(2-Aminophenyl)-2,4,6-trinitrobenzamide

Chemical compound data from PubChem database. IUPAC Name: trimethyl-[(6-trimethylsilyloxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl)oxy]silane. Molecular Formula: C12H26O4Si2. Molecular Weight: 290.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
2011 CMHS Uniform Reporting System (URS) Output Tables for Arizona

Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for 2011. The Uniform Reporting System (URS) is a state and national reporting system collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
Federal Fiscal Year 2023 Title IV-B, Subpart 2 Funding Available to Develop and Enhance or to Evaluate Kinship Navigator Programs

This Program Instruction (PI) provides guidance to state, territorial and tribal title IV-E agencies on the actions required to apply for title IV-B, subpart 2 funding to support the development, enhancement or evaluation of kinship navigator programs.

Metadata-only record linking to the original dataset. Open original dataset below.
Airway obstruction in asthma: does the response to a deep inspiration matter?

Airway hyperresponsiveness in asthma may not be a problem of too much airway smooth muscle strength. Rather, it may be a problem of too little of the factors that oppose muscle shortening. The weight of available evidence seems to support the idea that loss of the dilating response to a deep inspiration may play a central role in this process, and that the locus of the response is within the airway smooth muscle cell. Bridge dynamics and plastic reorganization of the smooth muscle cytoskeleton are the focus of this commentary; how these factors interact and details about underlying mechanisms remain unclear.
Patent AT-E40081-T1: [Translated] LOW RADIANT GLAZING FOR AUTOMOBILES.

The invention relates to a pane coated with a metal oxide coating, particularly a pane for an automobile window. The inventive pane bears a coating on its face intended to be disposed on the interior of the vehicle, which coating is comprised of a metal oxide of low emissivity. Such a pane improves the physiological comfort of the passengers, particularly during cold periods.
Patent AT-E401132-T1: [Translated] SPRAYER WITH A CONTAINER OF ADJUSTABLE VOLUME

There is disclosed a sprayer with a changeable volume. The sprayer includes a container (10), a pump (20), a first pipe (21), a second pipe (22) and a nozzle (221). The container (10) includes an upper wall (12) and a lower wall (11). The upper wall (12) can be compressed while not containing water and is extensible for containing water. The lower wall (11) is connected to the upper wall (12). The pump (20) is positioned in a space (111) defined in the lower wall (11). The first pipe (21) is directed to the pump (20) from a space (121) defined in the upper wall (12). The second pipe (22) is directed to the exterior of the container (10) from the pump (20). The nozzle (221) is connected to the second pipe (22).
Synthesis and preliminary cytotoxicity study of a cephalosporin-CC-1065 analogue prodrug

Background
          Antibody-directed enzyme prodrug therapy (ADEPT) is a promising new approach to deliver anticancer drugs selectively to tumor cells. In this approach, an enzyme is conjugated to a tumor-specific antibody. The antibody selectively localizes the enzyme to the tumor cell surface. Subsequent administration of a prodrug substrate of the enzyme leads to the enzyme-catalyzed release of the free drug at the tumor site. The free drug will destroy the tumor cells selectively, thus, reducing side effects.
        
        
          Results
          A CC-1065 analogue was conjugated to a cephalosporin affording prodrug 2. The prodrug and its corresponding free drug, 1, have IC50 values of 0.9 and 0.09 nM, respectively, against U937 leukemia cells in vitro.
        
        
          Conclusions
          For the first time, a prodrug comprised of a cephalosporin and a CC-1065 analogue has been synthesized. The preliminary in vitro studies show that the prodrug was 10-fold less toxic than the free drug. Prodrug 2 has the potential to be useful in cancer treatment using the ADEPT approach.
Compound 525419: Isopentyl propyl disulfide

Chemical compound data from PubChem database. IUPAC Name: 3-methyl-1-(propyldisulfanyl)butane. Molecular Formula: C8H18S2. Molecular Weight: 178.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: acute phase response related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis

Rheumatoid arthritis (RA) patients experience a markedly increased frequency of cardiovascular disease. We evaluated cardiovascular risk profiles in 79 RA patients and in 39 age-matched and sex-matched osteoarthritis (OA) patients. Laboratory tests comprised ultrasensitive C-reactive protein (CRP) and fasting lipids. Insulin sensitivity (IS) was determined by the Quantitative Insulin Sensitivity Check Index (QUICKI) in all OA patients and in 39 of the RA patients. Ten RA patients were on glucocorticoids. RA patients exercised more frequently than OA patients (χ2 = 3.9, P < 0.05). Nine RA patients and one OA patient had diabetes (χ2 = 4.5, P < 0.05). The median CRP, the mean QUICKI and the mean high-density lipoprotein (HDL) cholesterol were 9 mg/l (range, 0.5–395 mg/l), 0.344 (95% confidence interval [CI], 0.332–0.355) and 1.40 mmol/l (95% CI, 1.30–1.49 mmol/l) in RA patients, respectively, as compared with 2.7 mg/l (range, 0.3–15.9 mg/l), 0.369 (95% CI, 0.356–0.383) and 1.68 mmol/l (95% CI, 1.50–1.85 mmol/l) in OA patients. Each of these differences was significant (P < 0.05). After controlling for the CRP, the QUICKI was similar in RA and OA patients (P = 0.07), while the differences in HDL cholesterol were attenuated but still significant (P = 0.03). The CRP correlated with IS, while IS was associated with high HDL cholesterol and low triglycerides in RA patients and not in OA patients. A high CRP (≥ 8 mg/l) was associated with hypertension (χ2 = 7.4, P < 0.05) in RA patients. RA glucocorticoid and nonglucocorticoid users did not differ in IS and lipids (P > 0.05). Excess cardiovascular risk in RA patients as compared with OA patients includes the presence of decreased IS and HDL cholesterol in RA patients. The latter is only partially attributable to the acute phase response. The CRP, IS, HDL cholesterol, triglycerides and hypertension are inter-related in RA patients, whereas none of these relationships were found in OA patients.
Flow cytometric assessment of the reactivity of a panel of monoclonal antibodies (mAb) against two populations of human dendritic cells (DC)

Background
          The identification of antigens on human DC has been a very difficult and elusive task because of the lack of appropriate reagents. Therefore, we evaluated by flow cytometry a panel of mAb that recognize antigens on human DC, aiming to determine the kinetics of DC antigen expression at 7, 14, 21 and 28 days in (i) Dermal DC like cells (Mo-DC) and (ii) Langerhans cell like DC (Mo-LC). In addition we aimed to identify markers for DC subpopulations.
        
        
          Results
          It was found at day 7, that mAb BG6, HP-F1, BU10, RFD-1, CMRF-44 recognized <20% of Mo-DC. In contrast, 7H5, ZM3.8, CDlb/c, 55K-2, MMR1.16, MMR190.BB3 and L25 reacted with >50% of Mo-DC. Moreover, 7H5, ZM3.8, CMRF-56, CDlb/c, 55K-2, MMR1.16, MMR190.BB3 and L25 showed increased MFI reactivity against Mo-DC. mAb BG6, BU10 and CMRF-44 recognized <20% Mo-LC while RFD-1 reacted with 21% of Mo-LC. In contrast, HP-F1 showed 87% of Mo-LC positive. Also, 7H5, ZM3.8, RFD-7, MR15-2, CDlb/c, 55K-2, MMR1.16, MMR190.BB3 and L25 reacted with >50% of Mo-LC. The increase in % of positive cells was paralleled by MFI increases.
          At day 14, fourteen mAb recognized >50% of the Mo-DC, while five recognized 20-50% of Mo-DC. BG6 reacted with 7% of the Mo-DC. Nineteen mAb recognized >48% of Mo-LC while BG6 had negative reactivity.
          At day 21 and 28, all mAb reacted with >20% of Mo-DC and yielded a significant MFI with Mo-DC. Also nineteen mAb yielded significant MFI with Mo-LC while RFD-7 did not.
        
        
          Conclusions
          The immunophenotyping assays demonstrated differences between the two DC populations as well as variations in the reactivity of the mAb at diverse time points, suggesting the existence of subpopulations within the Mo-DC and Mo-LC.
15th NCCAN Commissioner's Award Book

The ACYF 2005 Commissioner's Awards book provides descriptions and photographs of the honorees from 41 states, the District of Columbia, and 2 territories who were recognized for their exceptional contributions to the prevention and treatment of child abuse and neglect. The ACYF Commissioner's Awards are presented every 2 years in association with NCCAN. Nominations are made by the governors of states and territories.

Metadata-only record linking to the original dataset. Open original dataset below.
Rate PUF - PY2020

The Rate PUF (Rate-PUF) is one of the files that make up the Marketplace PUF. The Rate-PUF contains plan-level data on individual rates based on an eligible subscriber’s age, tobacco use, and geographic location. These data either originate from the Rate Table template (i.e., template field), an Excel based form used by issuers to describe their plans in the QHP/SADP application process, or were generated by CCIIO for use in data processing (i.e., system-generated).
2010 State Profile — Wyoming

This state profile includes data from facilities in Wyoming that reported to N-SSATS for the survey reference date March 31, 2010. Data were collected on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse treatment facilities (both public and private) in Wyoming. In Wyoming, 60 substance abuse treatment facilities were included in the 2010 N-SSATS, reporting that there were 3,248 clients in substance abuse treatment on March 31, 2010. The survey response rate in Wyoming was 96.9%.
Program Instruction (PI-10-11)

This Program Instruction (PI) provides instruction on the Fostering Connections to Success and Increasing Adoptions Act of 2008 (Public Law 110-351) Comprehensive Guidance, Titles IV-B and IV-E Plan Requirements, Title IV-E Plan Amendment – Definition of “Child”, Extension of Title IV-E Assistance, Patient Protection and Affordable Care Act (Public Law (P.L.) 111-148).

Metadata-only record linking to the original dataset. Open original dataset below.
Patent AT-E400218-T1: [Translated] METHOD FOR ASSESSING IRREGULAR HEARTBEATS

A method for judging irregular heartbeat performs a measurement step to measure a plurality of heartbeat pulses within a time period for a user, and to measure inter-pulse durations and total pulse numbers. The method further performs a calculation step to calculate an averaged inter-pulse duration and a heartbeat number. Afterward, the method performs a first-stage judgment step to judge whether the measured pulse number is sufficient. When the first-stage judgment step is matched, a second-stage judgment step is performed. The second-stage judgment step judges irregular heartbeat condition by comparing the averaged inter-pulse duration with each inter-pulse duration. Finally, this method performs a display step to show a sign of irregular heartbeat when the irregular heartbeat condition is matched. This method can solve inaccuracy problem due to preset threshold.
Noninferiority trials

In one of the biggest dilemmas facing cardiovascular clinical research, clinical trials are increasingly being required to show benefits on clinical end-points rather than surrogate end-points, while at the same time the incremental benefits of newer treatments are getting smaller. These two factors have a huge impact on sample size, which has led some investigators to design trials to show that the new treatment has an effect similar to that of the standard, rather than outright superiority. Recent examples of fibrinolytic trials that have demonstrated similar effects of two drugs are ASSENT (Assessment of the Safety and Efficacy of a New Thrombolytic)-2, GUSTO (Global Use of Strategies to Open Occluded Coronary Arteries)-III, and COBALT (Continuous Infusion Versus Double-Bolus Administration of Alteplase) [1,2,3,4]. However, as discussed by several authors [5,6,7,8], there are issues with trials of this type that make them considerably less credible than superiority trials.
Vermont 2016 Potential Areas for Addressing Service Gaps for Opioid Treatment

The purpose of the medication-assisted treatment (MAT) facility maps is to identify areas on a state-by-state basis that may be potentially underserved by existing treatment facilities. The maps are created with a methodology that seeks to include the highest potential need areas from individual counties so that county-level stakeholders are also informed. The maps are meant to be used as a tool for policy makers to determine potentially underserved areas—not as a definitive representation of these areas.
Compound 527749: 2,2,2-Trichloroethyl tridecanoate

Chemical compound data from PubChem database. IUPAC Name: 2,2,2-trichloroethyl tridecanoate. Molecular Formula: C15H27Cl3O2. Molecular Weight: 345.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Maryland 2016 Potential Areas for Addressing Service Gaps for Opioid Treatment

The purpose of the medication-assisted treatment (MAT) facility maps is to identify areas on a state-by-state basis that may be potentially underserved by existing treatment facilities. The maps are created with a methodology that seeks to include the highest potential need areas from individual counties so that county-level stakeholders are also informed. The maps are meant to be used as a tool for policy makers to determine potentially underserved areas—not as a definitive representation of these areas.
2011 CMHS Uniform Reporting System (URS) Output Tables for Vermont

Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for 2011. The Uniform Reporting System (URS) is a state and national reporting system collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
Skilled Nursing Facility All Owners

The Skilled Nursing Facility (SNF) All Owners dataset provides information on all owners of SNFs currently enrolled in Medicare. This data includes ownership information such as ownership name, ownership type, ownership address and ownership effective date.

 

On November 17, 2023, CMS published in the Federal Register a final rule titled, “Medicare and Medicaid Programs; Disclosures of Ownership and Additional Disclosable Parties Information for Skilled Nursing Facilities and Nursing Facilities; Medicare Providers’ and Suppliers’ Disclosure of Private Equity Companies and Real Estate Investment Trusts” (88 FR 80141). This final rule implements parts of section 1124(c) of the Act which requires SNFs to disclose detailed information about their ownership and management as well as additional data regarding: (1) other parties with which the SNF is associated; and (2) the ownership structures of these other parties.  Refer to Medicare Enrollment for Providers & Suppliers for more information on the Skilled Nursing Facility disclosure requirements.

 Section 6101(b) of the Affordable Care Act states that no later than 1 year after final regulations promulgated under section 1124(c) of the Act are published in the Federal Register, the Secretary shall make the information reported available to the public.

 On November 21, 2024 CMS updated this dataset to include this reported information.
National Survey of Substance Abuse Treatment Services (N-SSATS): 2018, Data on Substance Abuse Treatment Facilities

This report presents results from the 2018 National Survey of Substance Abuse Treatment Services (N-SSATS), an annual census of facilities providing substance abuse treatment. Conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA), N-SSATS is designed to collect data on the location, characteristics, and use of alcohol and drug abuse treatment facilities and services throughout the 50 states, the District of Columbia, and other jurisdictions. It is important to note that values in charts, narrative lists, and percentage distributions are calculated using actual raw numbers and rounded for presentation in this report; calculations using rounded values may produce different results.
Compound 527293: 1,2-Dimethyl-4-isobutylbenzene

Chemical compound data from PubChem database. IUPAC Name: 1,2-dimethyl-4-(2-methylpropyl)benzene. Molecular Formula: C12H18. Molecular Weight: 162.27. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 528857: 1-(Prop-1-enyldisulfanyl)-1-propylsulfanylpropane

Chemical compound data from PubChem database. IUPAC Name: 1-(prop-1-enyldisulfanyl)-1-propylsulfanylpropane. Molecular Formula: C9H18S3. Molecular Weight: 222.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E399647-T1: [Translated] PRINTER AND SUPPLY UNIT FOR SAID PRINTER

The invention relates to a printer for printing a substrate (12), comprising a print unit and a supply unit for holding a substrate and delivering said substrate for transport to the print unit, wherein the supply unit is provided with a member for receiving a core (11) on which the substrate is wound, such that after reception by the member said core is functionally connected to a motor (200) for rotatably driving the core, and a downstream transport nip (31) for engaging and transporting an unwound part of the substrate which nip for the driving thereof is functionally connected to the said motor, wherein the transmission from the motor to the core and the nip respectively is such that on transport of the substrate to the print unit only the nip is actively driven by the motor and on the return of the substrate for winding thereof on the core both the core and the nip are actively driven by the motor, the core winding up as many metres of substrate per second as the nip returns.
2014 CMHS Uniform Reporting System (URS) Table for Republic of Palau

2014 Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for the Republic of Palau. The URS associated state reporting system is collected annually to support the Community Mental Health Services Block Grant program. Associated state Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
Compound 526605: [3-Acetyloxy-5-methoxy-2-(methoxymethyl)oxan-4-yl] acetate

Chemical compound data from PubChem database. IUPAC Name: [3-acetyloxy-5-methoxy-2-(methoxymethyl)oxan-4-yl] acetate. Molecular Formula: C12H20O7. Molecular Weight: 276.28. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 526381: Butyl hexyl phthalate

Chemical compound data from PubChem database. IUPAC Name: 1-O-butyl 2-O-hexyl benzene-1,2-dicarboxylate. Molecular Formula: C18H26O4. Molecular Weight: 306.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 525192: Heptyl pentyl terephthalate

Chemical compound data from PubChem database. IUPAC Name: 4-O-heptyl 1-O-pentyl benzene-1,4-dicarboxylate. Molecular Formula: C20H30O4. Molecular Weight: 334.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.